Zevra Therapeutics received a priority review voucher for Miplyffa, the first FDA-approved treatment for the rare metabolic disorder Niemann Pick disease type C. Though Zevra has other drug candidates that could benefit from the voucher, the biotech is selling it to an undisclosed buyer. The post Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug…
That is the title of a paper by Arnold and Priestley (2025). They examine whether gun purchase wait periods impact suicide rates using both variation in gun laws by state over time as well as variation in a county’s distance to the nearest state without a waiting period. First, some background on US gun purchase…
From Tyler Cowen at Marginal Revolution: One of the problems with an RFK Jr. ascendancy is that his core views, which run strongly against vaccines and pharmaceuticals, make it unlikely that any of these reimbursement revisions will be done in a rational or scientific way. The best evidence indicates that pharmaceuticals are a relatively cost-effective ways of saving…
This brief examines the legal considerations for physicians providing abortion care, including criminal and professional penalties, as well as the potential for medical malpractice lawsuits for delayed care to patients due to bans and prosecution for violation of abortion bans across state lines.
Nearly half (46%) of the public says that they expect the new tax and budget law signed by President Trump earlier this month to generally hurt them and their families, nearly twice the share (26%) who say it will generally help, a new KFF Health Tracking Poll finds. Among people who rely on Medicaid for…More
Insmed’s Brinsupri is the first drug specifically approved for treating non-cystic fibrosis bronchiectasis, a progressive and potentially fatal lung disorder. The drug, licensed from AstraZeneca, inhibits activation of neutrophils, white blood cells that play a role in inflammatory and immune responses. The post Chronic Lung Disease in Medical Literature for More Than 200 Years Finally…
Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion. The post Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M appeared first on MedCity News.
More effective and proactive care requires a framework that will enable the U.S. healthcare system to better meet the inevitable challenges of an aging population and pave the way for a sustainable and equitable future. Monitoring and other digital health enabled tools are helping to build that framework by offering a new medium for care…
The shift to a VBC model represents more than an evolution in healthcare delivery – it demands a fundamental redesign of our healthcare system and the economic models to support it. The post Unlocking Success in Value-Based Care: Why Focusing on Specialized Populations is Key appeared first on MedCity News.
Novo Holdings led the Series A investment in Kivu Biosciences, developer of next-generation antibody drug conjugates for solid tumors. The startup’s ADCs and technology were licensed from Synaffix, a Lonza subsidiary. The post Precision Oncology Startup Kivu Unveils $92M for More Stable & Durable ADC Cancer Drugs appeared first on MedCity News.